|Day Low/High||0.67 / 0.72|
|52 Wk Low/High||0.49 / 1.40|
-- Based on Positive Safety Data and Preliminary Signs of Efficacy, Study Expected to Advance to Phase 2 Portion in Early 2016 --
Adds Broad Finance and Operating Experience to Company's New Leadership
OXiGENE (OXGN) shares are rising after the company announced that the FDA gave preliminary approval for the method of its phase 3 cancer treatment study.
Dai Chaplin Becomes Chief Scientific Officer
Strengthened Cash Position; Fosbretabulin and OXi4503 Clinical Programs Advancing